Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology, Basic Science Track

Immuno-PET imaging of the programmed cell death-1 ligand (PD-L1) using the therapeutic mAb, avelumab

Elaine Jagoda, Falguni Basuli, Mark Williams, Ana Opina, Karen Wong, Stephen Adler, Anita Ton, Lawrence Szajek, Olga Vasalatiy, Biying Xu, Rolf Swenson and Peter Choyke
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 178;
Elaine Jagoda
4Molecular Imaging Program National Cancer Institute Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Falguni Basuli
5NIH/IPDC Rockville MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Williams
2Leidos Biomedical Research Inc. Frederick MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Opina
5NIH/IPDC Rockville MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Wong
4Molecular Imaging Program National Cancer Institute Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Adler
3Clinical Research Directorate/Clinical Monitoring Research Program Leidos Biomedical Research Inc. Frederick MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anita Ton
4Molecular Imaging Program National Cancer Institute Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence Szajek
1PET department Clinical Center, NIH Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olga Vasalatiy
5NIH/IPDC Rockville MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Biying Xu
5NIH/IPDC Rockville MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rolf Swenson
5NIH/IPDC Rockville MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Choyke
4Molecular Imaging Program National Cancer Institute Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Article Figures & Data

Figures

  • Tables
  • Figure1
    • Download figure
    • Open in new tab
    • Download powerpoint

Tables

  • Figures
  • Table 1. Effects of PD-L1 mAb dose escalation on Zr-89 PD-L1 mAb Tissue:Muscle ratios

    Tissue: Muscle Ratios 3 d post injection [mean (SD); n=5,6]
    PD-L1 mAb dose (ug) [coinjected with Zr-89 PD-L1 mAb (2 ug) ]0102040400
    Spleen42.6 (8.4)39.5 (10.8)23.6 (3.5)9.2 (1.8)4.4 (0.4)
    Lymph nodes9.4 (1.6)11.3 (3.9)43.3 (9.7)19.4 (4.4)11.5 (2.2)
    MDA-MB231 tumor3.1 (0.6)2.2 (0.4)10.6 (2.1)10.0 (1.7)8.9 (2.3)
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 58, Issue supplement 1
May 1, 2017
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Immuno-PET imaging of the programmed cell death-1 ligand (PD-L1) using the therapeutic mAb, avelumab
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Immuno-PET imaging of the programmed cell death-1 ligand (PD-L1) using the therapeutic mAb, avelumab
Elaine Jagoda, Falguni Basuli, Mark Williams, Ana Opina, Karen Wong, Stephen Adler, Anita Ton, Lawrence Szajek, Olga Vasalatiy, Biying Xu, Rolf Swenson, Peter Choyke
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 178;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Immuno-PET imaging of the programmed cell death-1 ligand (PD-L1) using the therapeutic mAb, avelumab
Elaine Jagoda, Falguni Basuli, Mark Williams, Ana Opina, Karen Wong, Stephen Adler, Anita Ton, Lawrence Szajek, Olga Vasalatiy, Biying Xu, Rolf Swenson, Peter Choyke
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 178;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology, Basic Science Track

  • Imaging adult glioma with 68Ga-citrate PET/MR
  • Evaluation of L-1-[18F]Fluoroethyl-Tryptophan for PET Imaging of Cancer
  • Pretargeted radioimmunotherapy with 225Ac-proteus-DOTA hapten.
Show more Oncology, Basic Science Track

Imaging the Immune System and Immunotherapy Response

  • ImmunoPET of CTLA-4 expression in murine models of non-small cell lung cancer
  • PET imaging for assessing the differential uptake of a CD20-specific monoclonal antibody in B cell lymphoma
  • Hematopoietic stem cell homing to bone injuries observed with Zr-89 oxine positron emission tomographic imaging.
Show more Imaging the Immune System and Immunotherapy Response

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire